Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples

被引：15

作者：

de Bruijn, P ^{[1
]}

Willems, EW ^{[1
]}

Loos, WJ ^{[1
]}

Verweij, J ^{[1
]}

Sparreboom, A ^{[1
]}

机构：

[1] Erasmus MC Daniel den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands

来源：

ANALYTICAL BIOCHEMISTRY | 2004年 / 328卷 / 01期

关键词：

D O I：

10.1016/j.ab.2004.01.007

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

[No abstract available]

引用

页码：84 / 86

页数：3

共 7 条

[1] Glucuronic acid conjugates [J].

Bedford, CT .

JOURNAL OF CHROMATOGRAPHY B, 1998, 717 (1-2) :313-326

[2]

Byrd G D, 2000, Drug Metabol Drug Interact, V16, P281

[3] Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection [J].

deBruijn, P ;

Verweij, J ;

Loos, WJ ;

Nooter, K ;

Stoter, G ;

Sparreboom, A .

JOURNAL OF CHROMATOGRAPHY B, 1997, 698 (1-2) :277-285

[4] UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity [J].

Iyer L. ;

Das S. ;

Janisch L. ;

Wen M. ;

Ramírez J. ;

Karrison T. ;

Fleming G.F. ;

Vokes E.E. ;

Schilsky R.L. ;

Ratain M.J. .

The Pharmacogenomics Journal, 2002, 2 (1) :43-47

[5]

Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182

[6]

Rivory LP, 1995, CANCER CHEMOTH PHARM, V36, P176

[7] Irinotecan in the treatment of colorectal cancer: Clinical overview [J].

Vanhoefer, U ;

Harstrick, A ;

Achterrath, W ;

Cao, SS ;

Seeber, S ;

Rustum, YM .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1501-1518

← 1 →